Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GSK2110183 Clear all
Completed Phase 2 Interventional

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

NCT01395004
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Nov 9, 2026, 4:18 PM EST
Completed Phase 1 Interventional

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

NCT01428492
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GSK2110183, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Nov 9, 2026, 4:18 PM EST
Completed Phase 2 Interventional Results available

Continuation Study of the Oral AKT Inhibitor GSK2110183

NCT01531894
View directory record Official record
Conditions
Cancer
Interventions
GSK2110183 (afuresertib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Nov 9, 2026, 4:18 PM EST
Completed Phase 1 Interventional

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

NCT01476137
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2110183
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Nov 9, 2026, 4:18 PM EST